andecaliximab + leucovorin + oxaliplatin + 5-fluorouracil + bevacizumab

This is a combination therapy consisting of **andecaliximab**, **leucovorin**, **oxaliplatin**, **5-fluorouracil** (5-FU), and **bevacizumab**, used investigationally or in clinical trials for cancer treatment, primarily colorectal cancer. - **Andecaliximab** is a monoclonal antibody targeting matrix metalloproteinase-9 (MMP9), designed to inhibit tumor progression and metastasis. - **Leucovorin** (folinic acid) enhances the effectiveness of 5-fluorouracil. - **Oxaliplatin** is a platinum-based chemotherapeutic agent causing DNA crosslinking and apoptosis. - **5-fluorouracil** is a pyrimidine analog that inhibits thymidylate synthase, disrupting DNA synthesis. - **Bevacizumab** is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis, and is approved for use in combination with oxaliplatin, leucovorin, and 5-fluorouracil in metastatic colorectal cancer[1][3][5][6].